✦ LIBER ✦

Reductions in Post-Prandial Glucagon by the GLP-1 Receptor Agonist Lixisenatide Correlate to Reductions in PPG and A1C in Patients with Type 2 Diabetes Mellitus

✍ Scribed by Aronson, Ronnie; Galstyan, Gagik; Gautier, Jean-Francois; Giorgino, Francesco; Gomez-Peralta, Fernando; Krebs, Michael; Nikonova, Elena; Stager, William; Vargas, Hernando; Ahrén, Bo

Book ID: 126834535
Publisher: Canadian Diabetes Association
Year: 2014
Tongue: English
Weight: 233 KB
Volume: 38
Category: Article
ISSN: 1499-2671
DOI: 10.1016/j.jcjd.2014.07.025

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A glucagon-like peptide-1 (GLP-1) recept

A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus

✍ S. K. Thondam; D. J. Cuthbertson; B. S. Aditya; I. A. MacFarlane; J. P. Wilding; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

Efficacy and safety of the glucagon-like

Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus

✍ Van Gaal, Luc; Souhami, Elisabeth; Zhou, Tianyue; Aronson, Ronnie 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 657 KB

Dose-dependent effects of the once-daily

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

✍ R. E. Ratner; J. Rosenstock; G. Boka; on behalf of the DRI6012 Study Investigato 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 202 KB

Two years of treatment with liraglutide,

Two years of treatment with liraglutide, a human GLP-1 analogue, offers sustained and greater reduction with HbA1c, FPG, PPG and weight compared with glimepiride, with lower glycaemic risk, in patients with type 2 diabetes: LEAD-3 extension study

✍ Garber, A.; Henry, R.; Ratner, R.E.; Hale, P.; Chang, C.T.; Bode, B. 📂 Article 📅 2009 🏛 Canadian Diabetes Association 🌐 English ⚖ 438 KB

Pharmacokinetics, safety, and efficacy o

Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature

✍ Giorda, Carlo B.; Nada, Elisa; Tartaglino, Barbara 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 336 KB

Erratum to: Pharmacokinetics, safety, an

Erratum to: Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature

✍ Giorda, Carlo B.; Nada, Elisa; Tartaglino, Barbara 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 154 KB